For sales

Highlights from the Week of 04th May – 11th May in the world of pharma and healthcare!

Highlights from the week of 4th May - 11th May Lannett ( FDA, Approval ) FDA approves Lanex Biologics’ subsidiary Lannett and Sunshine Lake Pharma's interchangeable biosimilar, LANGLARA, to treat adult and pediatric patients with type 1 diabetes mellitus and adults with type 2 diabetes mellitus Bristol Myers Squibb ( EU, Approval ) EC grants approval to Bristol Myers Squibb's SOTYKTU, a once-daily, oral, selective TYK2 inhibitor to treat active PsA in adults with inadequate or intolerant response to DMARD therapy Biocon ( Health Canada, Approval ) Biocon gets Health Canada approval for its micafungin injection, USP, 50 mg and 100 mg for the treatment and as a prophylaxis of various Candida infections in patients undergoing hematopoietic stem cell transplantation Merck ( Acquisition ) Merck acquires Terns Pharmaceuticals along with its Breakthrough Therapy Designation drug TERN-701, a potential treatment option for certain patients with chronic myeloid leukemia All logos and trademarks remain the intellectual properties of their respective owners
Download

Connect with us

Please fill in the information below, and we'll get back to you.